Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

The discovery of IDX21437: Design, synthesis and antiviral evaluation of 2'-α-chloro-2'-β-C-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors.

Alexandre FR, Badaroux E, Bilello JP, Bot S, Bouisset T, Brandt G, Cappelle S, Chapron C, Chaves D, Convard T, Counor C, Da Costa D, Dukhan D, Gay M, Gosselin G, Griffon JF, Gupta K, Hernandez-Santiago B, La Colla M, Lioure MP, Milhau J, Paparin JL, Peyronnet J, Parsy C, Pierra Rouvière C, Rahali H, Rahali R, Salanson A, Seifer M, Serra I, Standring D, Surleraux D, Dousson CB.

Bioorg Med Chem Lett. 2017 Sep 15;27(18):4323-4330. doi: 10.1016/j.bmcl.2017.08.029. Epub 2017 Aug 16.

PMID:
28835346
2.

Synthesis of potent and broad genotypically active NS5B HCV non-nucleoside inhibitors binding to the thumb domain allosteric site 2 of the viral polymerase.

Pierra Rouvière C, Amador A, Badaroux E, Convard T, Da Costa D, Dukhan D, Griffe L, Griffon JF, LaColla M, Leroy F, Liuzzi M, Loi AG, McCarville J, Mascia V, Milhau J, Onidi L, Paparin JL, Rahali R, Sais E, Seifer M, Surleraux D, Standring D, Dousson C.

Bioorg Med Chem Lett. 2016 Sep 15;26(18):4536-4541. doi: 10.1016/j.bmcl.2016.01.042. Epub 2016 Jan 22.

PMID:
27520942
3.

Design, synthesis and antiviral evaluation of 2'-C-methyl branched guanosine pronucleotides: the discovery of IDX184, a potent liver-targeted HCV polymerase inhibitor.

Sizun G, Pierra C, Peyronnet J, Badaroux E, Rabeson C, Benzaria-Prad S, Surleraux D, Loi AG, Musiu C, Liuzzi M, Seifer M, Standring D, Sommadossi JP, Gosselin G.

Future Med Chem. 2015;7(13):1675-700. doi: 10.4155/fmc.15.96. Epub 2015 Oct 1.

PMID:
26424162
4.

Single- and repeat-dose toxicity of IDX14184, a nucleotide prodrug with antiviral activity for hepatitis C viral infection, in mice, rats, and monkeys.

Luo S, Rush R, Standring D.

Hum Exp Toxicol. 2016 May;35(5):472-90. doi: 10.1177/0960327115592939. Epub 2015 Jul 2.

PMID:
26138064
5.

Pharmacokinetics of IDX184, a liver-targeted oral prodrug of 2'-methylguanosine-5'-monophosphate, in the monkey and formulation optimization for human exposure.

Pan-Zhou XR, Mayes BA, Rashidzadeh H, Gasparac R, Smith S, Bhadresa S, Gupta K, Cohen ML, Bu C, Good SS, Moussa A, Rush R.

Eur J Drug Metab Pharmacokinet. 2016 Oct;41(5):567-74. doi: 10.1007/s13318-015-0267-4. Epub 2015 Apr 22.

PMID:
25898809
6.

Overcoming stability challenges in the quantification of tissue nucleotides: determination of 2'-C-methylguanosine triphosphate concentration in mouse liver.

Rashidzadeh H, Bhadresa S, Good SS, Larsson Cohen M, Gupta KS, Rush WR.

Biol Pharm Bull. 2015;38(3):380-8. doi: 10.1248/bpb.b14-00565.

7.

Stereoselective cyclopropanation in the synthesis of 3'-deoxy-3'-C-hydroxymethyl-2',3'-methylene-uridine.

Komsta Z, Mayes BA, Moussa A, Shelbourne M, Stewart A, Tyrrell AJ, Wallis LL, Weymouth-Wilson AC, Yurek-George A.

Org Lett. 2014 Sep 19;16(18):4878-80. doi: 10.1021/ol502383c. Epub 2014 Sep 11.

PMID:
25210994
8.

Structure-based design of a novel series of azetidine inhibitors of the hepatitis C virus NS3/4A serine protease.

Parsy C, Alexandre FR, Brandt G, Caillet C, Cappelle S, Chaves D, Convard T, Derock M, Gloux D, Griffon Y, Lallos L, Leroy F, Liuzzi M, Loi AG, Moulat L, Musiu C, Rahali H, Roques V, Seifer M, Standring D, Surleraux D.

Bioorg Med Chem Lett. 2014 Sep 15;24(18):4444-4449. doi: 10.1016/j.bmcl.2014.08.002. Epub 2014 Aug 9.

PMID:
25155387
9.

In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.

Bilello JP, Lallos LB, McCarville JF, La Colla M, Serra I, Chapron C, Gillum JM, Pierra C, Standring DN, Seifer M.

Antimicrob Agents Chemother. 2014 Aug;58(8):4431-42. doi: 10.1128/AAC.02777-13. Epub 2014 May 27.

10.

Synthesis of 2'-O,4'-C-alkylene-bridged ribonucleosides and their evaluation as inhibitors of HCV NS5B polymerase.

Chapron C, Glen R, La Colla M, Mayes BA, McCarville JF, Moore S, Moussa A, Sarkar R, Seifer M, Serra I, Stewart A.

Bioorg Med Chem Lett. 2014 Jun 15;24(12):2699-702. doi: 10.1016/j.bmcl.2014.04.050. Epub 2014 Apr 19.

PMID:
24815510
11.

A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4.

Vince B, Hill JM, Lawitz EJ, O'Riordan W, Webster LR, Gruener DM, Mofsen RS, Murillo A, Donovan E, Chen J, McCarville JF, Sullivan-Bólyai JZ, Mayers D, Zhou XJ.

J Hepatol. 2014 May;60(5):920-7. doi: 10.1016/j.jhep.2014.01.003. Epub 2014 Jan 14.

12.

Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects.

Zhou XJ, Pietropaolo K, Chen J, Khan S, Sullivan-Bólyai J, Mayers D.

Antimicrob Agents Chemother. 2011 Jan;55(1):76-81. doi: 10.1128/AAC.01101-10. Epub 2010 Nov 8.

13.

Synthesis and antiviral evaluation of 4'-C-azidomethyl-beta-D-ribofuranosyl purine and pyrimidine nucleosides.

Griffon JF, Dumas A, Storer R, Sommadossi JP, Gosselin G.

Nucleosides Nucleotides Nucleic Acids. 2009 May;28(5):435-49. doi: 10.1080/15257770903044531.

PMID:
20183594
14.

Evaluation of the role of three candidate human kinases in the conversion of the hepatitis C virus inhibitor 2'-C-methyl-cytidine to its 5'-monophosphate metabolite.

Golitsina NL, Danehy FT Jr, Fellows R, Cretton-Scott E, Standring DN.

Antiviral Res. 2010 Mar;85(3):470-81. doi: 10.1016/j.antiviral.2009.10.020. Epub 2009 Oct 31.

PMID:
19883694
15.

Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects.

Zhou XJ, Garner RC, Nicholson S, Kissling CJ, Mayers D.

J Clin Pharmacol. 2009 Dec;49(12):1408-16. doi: 10.1177/0091270009343698. Epub 2009 Sep 23.

PMID:
19776293
16.

Population pharmacokinetics of telbivudine and determination of dose adjustment for patients with renal impairment.

Zhou XJ, Ke J, Sallas WM, Farrell C, Mayers DL, Pentikis HS.

J Clin Pharmacol. 2009 Jun;49(6):725-34. doi: 10.1177/0091270009333555. Epub 2009 Apr 24.

PMID:
19395586
17.

Synthesis and antiviral evaluation of thieno[3,4-d]pyrimidine C-nucleoside analogues of 2',3'-dideoxy- and 2',3'-dideoxy-2',3'-didehydro-adenosine and -inosine.

Hamann M, Pierra C, Sommadossi JP, Musiu C, Vargiu L, Liuzzi M, Storer R, Gosselin G.

Bioorg Med Chem. 2009 Mar 15;17(6):2321-6. doi: 10.1016/j.bmc.2009.02.011. Epub 2009 Feb 14.

PMID:
19254848
18.

Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects.

Zhou XJ, Pietropaolo K, Damphousse D, Belanger B, Chen J, Sullivan-Bólyai J, Mayers D.

Antimicrob Agents Chemother. 2009 May;53(5):1739-46. doi: 10.1128/AAC.01479-08. Epub 2009 Feb 17.

19.

Synthesis of the first example of a nucleoside analogue bearing a 5'-deoxy-beta-D-allo-septanose as a seven-membered ring sugar moiety.

Sizun G, Dukhan D, Griffon JF, Griffe L, Meillon JC, Leroy F, Storer R, Sommadossi JP, Gosselin G.

Carbohydr Res. 2009 Mar 10;344(4):448-53. doi: 10.1016/j.carres.2008.12.019. Epub 2009 Jan 3.

PMID:
19147123
20.

Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir.

Seifer M, Patty A, Serra I, Li B, Standring DN.

Antiviral Res. 2009 Feb;81(2):147-55. doi: 10.1016/j.antiviral.2008.10.008. Epub 2008 Nov 24.

PMID:
19028525

Supplemental Content

Loading ...
Support Center